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Introduction
The aim of the project was to apply the John Hopkins
ACG case-mix system, Rx-PM model, to the Swedish
National Drug Register (period 2006-2008). Its intention
was to analyze and compare results between different
county councils, and analyze if drug use in the population
can be employed to approximate the need for care, and as
a tool to adjust the capitation payment system in the
county councils. This paper focuses on the comparisons
between the different county councils. Practical examples
and usage of data are presented.
Methods
The ACG-Rx system, based on the unique Rx-MG catego-
ries, is an Rx-based risk adjustment tool (NDC, ATC, Read
code) that can be used as a predictive model and to under-
stand patterns of medication use. Pharmaceutical utiliza-
tion is a proxy for underlying morbidity. The John
Hopkins ACG case mix system, Rx-PM model, is a group-
ing logic that uses drug utilization to measure the severity
of the underlying morbidity, the therapeutic goal of med-
ication use, and the duration of treatment to present phar-
macy data in a new perspective that had not been
available previously.
The tool can be used for disease/case management, profil-
ing (population and provider) and forecasting pharmacy
and total costs for large groups. The analysis included
Sweden's entire population (9 million persons) and their
usage of drugs (6.2 million patients annually). This
resulted in 29 million combinations of patients and used
ATC-codes for each year. Results have been grouped for
the periods 2006, 2007 and 2008. The analysis represents
an annual cost of 24-25 Billion SEK (approx. 25 Mill
Euro). The grouping went well in practice without any
coding issues.
Results
The analysis model involves five steps: 1) Actual phar-
macy cost and predicted pharmacy cost per county coun-
cil. The purpose of this analysis is to determine the cost
level. 2) Actual costs per inhabitant and predicted cost per
inhabitant per county council/municipality. The purpose
of this analysis is to determine the differences in con-
sumption. 3) Proportion of high-risk patients per munic-
ipality. The purpose of this analysis is to determine how
specific outliers influence the results. 4) Standard Morbid-
ity Rates (SMRs) for major Rx-MGs per county council.
The purpose of this analysis is to determine if specific
groups and practices influence the results. 5) Compari-
sons of specific Rx-MGs per county council. The purpose
of this analysis is to provide a detailed comparison on
practices and costs.
Conclusion
The Rx-model works well for Swedish data. The analysis
showed significant differences between county councils as
well as on the municipal level. Measures generated from
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the system could, therefore, be used in the Swedish bench-
marking model Open Comparisons.
The model also provides functionality for predicting
change in total cost. Comparison between predicted costs
from the Rx-model and the actual costs showed a low var-
iation (1%). The model provides a large amount of data
for analysis and usage in practice, i.e., specific analysis for
measuring costs for high-risk patients. More analysis with
diagnosis and cost data on the county council level is still
needed to prove if Rx-MG can be a useful tool for resource
allocation in a capitation model.
The combined models (Rx-PM + Dx-PM) with diagnoses
and pharmacy data are recommended for use. Pharmacy
data alone has a higher explanatory value than age and
gender, but it is still low in comparison with combined
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